Short Interest in Elekta AB (OTCMKTS:EKTAY) Rises By 345.3%

Elekta AB (OTCMKTS:EKTAY) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 16,311 shares, an increase of 345.3% from the July 15th total of 3,663 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 9,444 shares, the short-interest ratio is currently 1.7 days.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Elekta Price Performance

Shares of EKTAY opened at $5.46 on Wednesday. The business’s 50-day moving average is $5.15 and its two-hundred day moving average is $5.77. The company has a market capitalization of $2.01 billion, a P/E ratio of -34.12 and a beta of 1.01. Elekta has a fifty-two week low of $4.35 and a fifty-two week high of $6.93. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.68 and a current ratio of 0.87.

Elekta (OTCMKTS:EKTAY) last posted its earnings results on Thursday, May 28th. The company reported $0.06 EPS for the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%.The firm had revenue of $521.00 million for the quarter. Research analysts predict that Elekta will post 0.43 earnings per share for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.